# Beijing Center Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-center-technology-co

- Industry: Healthcare
- Headquarters: Guangzhou, China
- Website: www.miaoshou.com
- Total disclosed funding: $933M
- Latest round: Series F (Aug 3, 2021)
- Investors on record: 18

## About

Based in Guangzhou, China, and founded in 2015 by Daoliang Han and Tao He, Beijing Center Technology Co., Ltd., trading under the name Miaoshou Doctor, is a health care platform that provides communication services between doctors and patients. In August 2021, Beijing Yuanxin Technology Group Co., Ltd. raised CNY 1.5 million in Series F funding from new investors Ab Initio Capital, B Capital Group, BOC International (China), E Fund Management Co., Ltd, Hel Ved Capital Management, Sequoia Capital China, United Overseas Bank, and other returning investors.

The company's platform includes Miaoshou Doctor, Yuanxin Pharmacy, and Yuanxin Insurance service that delivers data-based medical insurance products to people. The main platform of the company, Miaoshou Doctor, enables patients to consult with doctors remotely and get a prescription recommendation. The platform's online store also allows customers to purchase over-the-counter medicine.

The company plans to expand its network of services and disease and management solutions, accelerate the construction of its digital hospitals, and continue the development of its portfolio of commercial health insurance products.

## Funding rounds

- Series F, Aug 3, 2021, $232M — OrbiMed Advisors, Hong Shan, United Overseas Bank, Qiming Venture Partners, BOC International (China), CITIC Securities, E Fund Management Co.,Ltd, B Capital, Index Capital, Kunling Capital, Archerman Capital, INCE Capital, Hel Ved Capital Management
- Series E, Feb 9, 2021, $465M — OrbiMed Advisors, Hong Shan, Qiming Venture Partners, China International Capital Corporation, Tencent Investment, CITIC Securities, Index Capital, E Fund Overseas Investment, Kunling Capital, Gopher Asset Management
- Series D, Jun 15, 2020, $85M — Hong Shan, Qiming Venture Partners, CITIC Securities, Index Capital, INCE Capital
- Series C, Jan 7, 2019, $73M — Hong Shan, StarQuest
- Series C, Apr 2, 2018, $79M — Hong Shan, Qiming Venture Partners, Tencent Investment, Kunling Capital
- Series A, Aug 4, 2015 — Hong Shan, Tencent Investment

## Investors

- Hong Shan — Series A, Series C, Series D, Series E, Series F
- Tencent Investment — Series A, Series C, Series E
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C, Series D, Series E, Series F
- Kunling Capital (https://capitalatlas.ai/funds/kunling-capital) — Series C, Series E, Series F
- StarQuest (https://capitalatlas.ai/funds/starquest) — Series C
- CITIC Securities — Series D, Series E, Series F
- Index Capital (https://capitalatlas.ai/funds/index-capital) — Series D, Series E, Series F
- INCE Capital (https://capitalatlas.ai/funds/ince-capital) — Series D, Series F
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series E, Series F
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series E
- E Fund Overseas Investment (https://capitalatlas.ai/funds/e-fund-overseas-investment) — Series E
- Gopher Asset Management (https://capitalatlas.ai/funds/gopher-asset-management) — Series E
- United Overseas Bank — Series F
- BOC International (China) (https://capitalatlas.ai/funds/boc-international-china) — Series F
- E Fund Management Co.,Ltd — Series F
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series F
- Archerman Capital (https://capitalatlas.ai/funds/archerman-capital) — Series F
- Hel Ved Capital Management — Series F